search
Back to results

First-Voided Urinary LH vs. GnRH-stimulation in Differentiating Slowly- From Rapidly Progressive-Precocious Puberty

Primary Purpose

Precocious Puberty, Gonadotropin-dependent

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Measurement of LH in first-voided urine
collection of first-voided urine sample for LH level
Sponsored by
Amnon Zung
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Precocious Puberty, Gonadotropin-dependent focused on measuring precocious puberty, urinary LH, GnRH stimulation test, gonadotropins

Eligibility Criteria

3 Years - 9 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Onset of puberty after 3 years of age in boys and girls
  • Onset of puberty before 8 years in girls and 9 years in boys

Exclusion Criteria:

  • Non-central precocious puberty
  • Congenital adrenal hyperplasia
  • Enuresis nocturne

Sites / Locations

  • Peditaric Endocrinology Unit, Kaplan Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

pubertal progression

Arm Description

A collection of first voided urine sample for the measurement of LH.

Outcomes

Primary Outcome Measures

Identification of first-voided urinary LH cutoff for the detection of pubertal advancement by comparison with GnRH stimulated gonadotropins

Secondary Outcome Measures

Levels first-voided urinary LH measurements in monitoring gonadotropin suppression during GnRHa therapy

Full Information

First Posted
February 21, 2013
Last Updated
February 25, 2013
Sponsor
Amnon Zung
search

1. Study Identification

Unique Protocol Identification Number
NCT01800565
Brief Title
First-Voided Urinary LH vs. GnRH-stimulation in Differentiating Slowly- From Rapidly Progressive-Precocious Puberty
Official Title
Urinary LH in the Diagnosis of Precocious Puberty
Study Type
Interventional

2. Study Status

Record Verification Date
February 2013
Overall Recruitment Status
Unknown status
Study Start Date
June 2006 (undefined)
Primary Completion Date
December 2013 (Anticipated)
Study Completion Date
December 2013 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Amnon Zung

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Precocious puberty (PP) in girls is classically defined by the onset of secondary sexual characteristics before eight years of age, but subsequent pubertal maturation can be quite varied. In many girls, PP takes a rapid course of progression (rapidly progressive precocious puberty; RP-PP) with an early menarche and fusion of the epiphyseal growth plates, leading eventually to a reduced final height if not treated. In a subset of girls with PP however, the growth rate slows to normal for age, skeletal maturation progresses in accordance with chronological age and there is little to no risk of impairment of final height (slowly progressive precocious puberty; SP-PP). Other conditions of non-progressive PP include premature breast budding and unsustained PP that is characterized by a spontaneous regression of sexual precocity. Due to their benign course, slowly progressive (SP) PP and other non-progressive forms of PP do not warrant therapy with GnRH agonists. Differentiating these forms from RP-PP is therefore essential to prevent unnecessary intervention in a population that accounts for at least 50% of girls with PP. A distinction between these forms of PP may be difficult on clinical grounds however, since all these patients may present initially as isolated breast development. The gold standard for the diagnosis of true (central) PP is the measurement of gonadotropins following GnRH stimulation test. There is however an overlap between prepubertal and early pubertal values and between girls with premature breast budding and progressive PP. It was suggested therefore that progressive pubertal development and growth acceleration should be documented over a 3- to 6-months period before GnRHa therapy in initiated. More than a decade ago several studies demonstrated that urinary gonadotropins are age related and significantly increased during puberty. It has been suggested that urinary gonadotropins measurements can be used for differential diagnosis of pubertal disorders. This is based on the assumption that gradual elevation of nocturnal LH secretion prior to and at the onset of puberty can be reflected by first-voided urinary LH (ULH). In this prospective study, the investigators aimed to evaluate the value of first-voided ULH measurements in predicting pubertal course and differentiating SP-PP from RP-PP, by comparison to GnRH-stimulated gonadotropins.
Detailed Description
Precocious puberty (PP) in girls is classically defined by the onset of secondary sexual characteristics before eight years of age, but subsequent pubertal maturation can be quite varied. In many girls, PP takes a rapid course of progression (rapidly progressive precocious puberty; RP-PP) with an early menarche and fusion of the epiphyseal growth plates, leading eventually to a reduced final height if not treated. In a subset of girls with PP however, the growth rate slows to normal for age, skeletal maturation progresses in accordance with chronological age and there is little to no risk of impairment of final height (slowly progressive precocious puberty; SP-PP). Other conditions of non-progressive PP include premature thelarche and unsustained PP that is characterized by a regression of sexual precocity. Due to their benign course, slowly progressive (SP) PP and other non-progressive forms of PP do not warrant therapy with GnRH agonists. Differentiating these forms from RP-PP is therefore essential to prevent unnecessary intervention in a population that accounts for at least 50% of girls with PP. A distinction between these forms of PP may be difficult on clinical grounds however, since all these patients may present initially as isolated breast development. The gold standard for the diagnosis of true (central) PP is the measurement of gonadotropins following GnRH stimulation test , where peak LH and peak LH/FSH ratio are the most valuable diagnostic parameters. There is however an overlap between prepubertal and early pubertal values and between girls with premature thelarche and progressive PP. It was suggested therefore that progressive pubertal development and growth acceleration should be documented over a 3- to 6-months period before GnRHa therapy in initiated. More than a decade ago, along with the development of high-sensitive immunoassay for gonadotropins that replaced the RIA, Demir and colleagues have shown that urinary gonadotropins are age related and significantly increased during puberty. It has been suggested by others that urinary gonadotropins measurements can be used for differential diagnosis of pubertal disorders. This is based on the assumption that gradual elevation of nocturnal LH secretion prior to and at the onset of puberty can be reflected by first-voided urinary LH (ULH). In this prospective study, the investigators aimed to evaluate the value of first-voided ULH measurements in predicting pubertal course and differentiating SP-PP from RP-PP, by comparison to GnRH-stimulated gonadotropins.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Precocious Puberty, Gonadotropin-dependent
Keywords
precocious puberty, urinary LH, GnRH stimulation test, gonadotropins

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Care Provider
Allocation
N/A
Enrollment
65 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
pubertal progression
Arm Type
Other
Arm Description
A collection of first voided urine sample for the measurement of LH.
Intervention Type
Other
Intervention Name(s)
Measurement of LH in first-voided urine
Intervention Description
participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
Intervention Type
Other
Intervention Name(s)
collection of first-voided urine sample for LH level
Intervention Description
participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
Primary Outcome Measure Information:
Title
Identification of first-voided urinary LH cutoff for the detection of pubertal advancement by comparison with GnRH stimulated gonadotropins
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Levels first-voided urinary LH measurements in monitoring gonadotropin suppression during GnRHa therapy
Time Frame
2 years
Other Pre-specified Outcome Measures:
Title
Identification of first-voided urinary LH cutoff for differentiating pseudothelarche from true breast budding, compared with GnRH stimulated gonadotropins
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
9 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Onset of puberty after 3 years of age in boys and girls Onset of puberty before 8 years in girls and 9 years in boys Exclusion Criteria: Non-central precocious puberty Congenital adrenal hyperplasia Enuresis nocturne
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amnon Zung, MD
Phone
972-8-9441260
Email
amzung2@bezeqint.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amnon Zung, MD
Organizational Affiliation
Pediatirc Endocrinology Unit, Kaplan Medical Center, affiliated with the Hebrew University of Jerusalem, Israel
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peditaric Endocrinology Unit, Kaplan Medical Center
City
Rehovot
ZIP/Postal Code
76100
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amnon Zung, MD
Phone
972-8-9441260
Email
amzung2@bezeqint.net
First Name & Middle Initial & Last Name & Degree
Amnon Zung, MD

12. IPD Sharing Statement

Learn more about this trial

First-Voided Urinary LH vs. GnRH-stimulation in Differentiating Slowly- From Rapidly Progressive-Precocious Puberty

We'll reach out to this number within 24 hrs